Evogene
EVGN
28 hedge funds and large institutions have $2.55M invested in Evogene in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.03% less ownership
Funds ownership: 0.8% → 0.78% (-0.03%)
3% less funds holding
Funds holding: 29 → 28 (-1)
16% less capital invested
Capital invested by funds: $3.04M → $2.55M (-$483K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.1K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$9.18K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$6.28K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.71K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$2.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$45.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.3K |
| 3 |
JP Morgan Chase
New York
|
-$17.1K |
| 4 |
MCC
Malaga Cove Capital
Pv Estates,
California
|
-$9K |
| 5 |
VF
Virtu Financial
New York
|
-$9K |
EVGN Hedge Fund Activity: Q2 2024 in Review
28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2024, worth a combined $2.55M — down 16% from $3.04M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EVGN and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 8 added.
The largest buyer was Susquehanna International Group, adding an estimated $20.1K. The largest seller was Morgan Stanley, cutting an estimated $45.8K.
- 28 institutional investors held Evogene (EVGN) as of Q2 2024, down from 29 in Q1 2024.
- Funds reported $2.55M of Evogene stock for Q2 2024, down 16% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q2 2024 and 4 closed out, a net change of -1 holder.
- The largest Evogene buyer in Q2 2024 was Susquehanna International Group, an estimated $20.1K added.
- The largest Evogene seller in Q2 2024 was Morgan Stanley, an estimated $45.8K sold.
Based on aggregated 13F filings for Q2 2024.